A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC

The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).

Trial Details

NCT ID
NCT06010329
Phase
PHASE2
Sponsor
Teligene US
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • Sutetinib Maleate Capsule
Locations (sample)
  • Glendale, California, United States|34.14251,-118.25508
  • La Jolla, California, United States|32.84727,-117.2742
  • Tampa, Florida, United States|27.94752,-82.45843
  • Athens, Georgia, United States|33.96095,-83.37794
  • Des Moines, Iowa, United States|41.60054,-93.60911

Key Eligibility Criteria

  • Age 18 years old and above, male or female
  • Histopathological and/or cytopathological confirmation of locally advanced or metastatic NSCLC
  • Confirmation that the tumor harbors an uncommon epidermal growth factor receptor (EGFR) mutation (tumor tissue biopsy)
  • At least one measurable lesion

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →